ALK基因抑制剂治疗非小细胞肺癌脑转移的研究进展

doi:10.3760/cma.j.issn.1673-422X.2017.06.018

摘要/Abstract

摘要： 间变性淋巴瘤激酶(ALK)重排是非小细胞肺癌（NSCLC）强有力的致癌驱动基因之一，伴ALK重排的NSCLC患者应用第一代ALK抑制剂如克唑替尼的治疗疗效要远远优于化疗。同时越来越多的研究报道了ALK抑制剂在伴有脑转移的NSCLC患者中的颅内有效率。然而尽管第一代ALK抑制剂治疗ALK阳性NSCLC脑转移有初步的临床数据，但在获得性耐药后，肿瘤出现不同程度的复发，给肿瘤患者的后续治疗带来新的挑战。新一代ALK抑制剂如艾乐替尼、色瑞替尼、AP26113和PF06463922的相继出现解决了这一问题。

关键词: 癌, 非小细胞肺, 肿瘤转移, 间变性淋巴瘤激酶融合基因抑制剂

Abstract: Anaplastic lymphoma kinase (ALK) rearrangement is one of the most potent carcinogenic genes in nonsmall cell lung cancer (NSCLC). The firstgeneration ALK inhibitor such as crizotinib is superior to chemotherapy for NSCLC patients with ALK rearrangement. At the same time, more and more studies have reported ALK inhibitors in brain metastases of NSCLC patients with intracranial efficiency. However, despite the initial clinical data of firstgeneration ALK inhibitors in the treatment of ALKpositive NSCLC with brain metastases, different degrees of recurrence of tumors after acquired resistance have posed new challenges for followup treatment of cancer patients. A new generation of ALK inhibitors, such as alectinib, ceritinib, AP26113 and PF06463922 have emerged to solve this problem.

Key words: Carcinoma, nonsmallcell lung, Neoplasm metastasis, Anaplastic lymphoma kinase fusion gene inhibitors

孙文宇，闫鹏飞，原颖丽，马克威. ALK基因抑制剂治疗非小细胞肺癌脑转移的研究进展[J]. 国际肿瘤学杂志, 2017, 44(6): 472-.

Sun Wenyu, Yan Pengfei, Yuan Yingli, Ma Kewei. Progress of ALK gene inhibitors in the treatment of brain metastases from nonsmall cell lung cancer[J]. Journal of International Oncology, 2017, 44(6): 472-.

参考文献

［1］ Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4ALK fusion gene in nonsmallcell lung cancer［J］. Nature, 2007, 448(7153): 561-566. DOI: 10.1038/nature05945. ［2］ Gainor JF, Varghese AM, Ou SH, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with nonsmall cell lung cancer［J］. Clin Cancer Res, 2013, 19(15): 4273-4281. DOI: 10.1158/10780432.CCR130318. ［3］ Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosisspecific tool to estimate survival for patients with brain metastases［J］. J Clin Oncol, 2012, 30(4): 419-425. DOI: 10.1200/JCO.2011.38.0527. ［4］ Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in nonsmallcell lung cancer［J］. N Engl J Med, 2010, 363(18): 1693-1703. DOI: 10.1056/NEJMoa1006448. ［5］ Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALKpositive nonsmallcell lung cancer: updated results from a phase 1 study［J］. Lancet Oncol, 2012, 13(10): 1011-1019. DOI: 10.1016/S14702045(12)703443. ［6］ Loong HH, Mok K, Leung LK, et al. Crizotinib in the management of advancedstage nonsmallcell lung cancer［J］. Future Oncol, 2015, 11(5): 735-745. DOI: 10.2217/fon.14.314. ［7］ Solomon BJ, Mok T, Kim DW, et al. Firstline crizotinib versus chemotherapy in ALKpositive lung cancer［J］. N Engl J Med, 2014, 371(23): 2167-2177. DOI: 10.1056/NEJMoa1408440. ［8］ Costa DB, Shaw AT, Ou SH, et al. Clinical experience with crizotinib in patients with advanced ALKrearranged nonsmallcell lung cancer and brain metastases［J］. J Clin Oncol, 2015, 33(17): 1881-1888. DOI: 10.1200/JCO.2014.59.0539. ［9］ Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib［J］. J Clin Oncol, 2011, 29(15): e443-e445. DOI: 10.1200/JCO.2010.34.1313. ［10］ Chun SG, Choe KS, Iyengar P, et al. Isolated central nervous system progression on Crizotinib: an Achilles heel of nonsmall cell lung cancer with EML4ALK translocation?［J］. Cancer Biol Ther, 2012, 13(14): 1376-1383. DOI: 10.4161/cbt.22255. ［11］ Metro G, Lunardi G, Floridi P, et al. CSF concentration of crizotinib in two ALKpositive nonsmallcell lung cancer patients with CNS metastases deriving clinical benefit from treatment［J］. J Thorac Oncol, 2015, 10(5): e26-e27. DOI: 10.1097/JTO.0000000000000468. ［12］ Sakamoto H, Tsukaguchi T, Hiroshima S, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant［J］. Cancer Cell, 2011, 19(5): 679-690. DOI: 10.1016/j.ccr.2011.04.004. ［13］ Kodama T, Tsukaguchi T, Yoshida M, et al. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance［J］. Cancer Lett, 2014, 351(2): 215-221. DOI: 10.1016/j.canlet.2014.05.020. ［14］ Kodama T, Hasegawa M, Takanashi K, et al. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases［J］. Cancer Chemother Pharmacol, 2014, 74(5): 1023-1028. DOI: 10.1007/s0028001425786. ［15］ Nanjo S, Nakagawa T, Takeuchi S, et al. In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4ALK lung cancer cell line. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases［J］. Cancer Sci, 2015, 106(3): 244-252. ［16］ Bartels AL, Kortekaas R, Bart J, et al. Bloodbrain barrier Pglycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration［J］. Neurobiol Aging, 2009, 30(11): 1818-1824. DOI: 10.1016/j.neurobiolaging.2008.02.002. ［17］ Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinibresistant ALKrearranged nonsmallcell lung cancer (AF002JG): results from the dosefinding portion of a phase 1/2 study［J］. Lancet Oncol, 2014, 15(10): 1119-1128. DOI: 10.1016/S14702045(14)703626. ［18］ Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALKrearranged advanced nonsmallcell lung cancer (AF001JP study): a singlearm, openlabel, phase 12 study［J］. Lancet Oncol, 2013, 14(7): 590-598. DOI: 10.1016/S14702045(13)701426. ［19］ Seto T, Hida T, Nakagawa K, et al. Antitumor activity of alectinib in crizotinib pretreated ALKrearranged NSCLC in JP28927 study［J］. Annals of Oncol, 2014, 25(4): 426-470. ［20］ Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in nonsmall cell lung cancer［J］. Cancer Discov, 2014, 4(6): 662-673. DOI: 10.1158/21598290.CD130846. ［21］ Shaw A, Mehra R, Tan D, et al. Evaluation of ceritinibtreated patients with anaplastic lymphoma kinase rearranged (ALK+) nonsmall cell lung cancer (NSCLC) and brain metastases in the ASCEND1 study［J］. Annals of Oncol, 2014, 2(4): 426-470. ［22］ Mok T, Spigel D, Felip E, et al. ASCEND2: a singlearm, openlabel, multicenter phase 2 study of ceritinib in adult patients (pts) with ALKrearranged (ALK+) nonsmall cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ)［J］. J Clin Oncol, 2015, 33(Suppl): abstr 8059. ［23］ Felip E, Orlov S, Park K, et al. ASCEND3: a singlearm, openlabel, multicenter phase Ⅱ study of ceritinib in ALKinave adult patients (pts) with ALKrearranged (ALK+) nonsmall cell lung cancer (NSCLC)［J］. J Clin Oncol, 2015, 33(Suppl): abstr 8060. ［24］ Shaw AT, Mehra R, Tan D, et al. Ceritinib (LDK378) for treatment of patients with ALKrearranged (ALK+) nonsmall cell lung cancer (NSCLC) and brain metastases (BM) in the ASCEND1 tria［J］.Neuro Oncol, 2014, 16 (suppl 5): 39. ［25］ Awad MM, Shaw AT. ALK inhibitors in nonsmall cell lung cancer: crizotinib and beyond［J］. Clin Adv Hematol Oncol, 2014, 12(7): 429-439. ［26］ Camidge DR, Bazhenova L, Salgia R, et al. Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ nonsmall cell lung cancer (NSCLC)［J］. Clin Oncol, 2015, 33(supple): abstr 8062. ［27］ Zou HY, Friboulet L, Kodack DP, et al. PF06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models［J］. Cancer Cell, 2015, 28(1): 70-81. DOI: 10.1016/j.ccell.2015.05.010. ［28］ Felip E, Bauer T, Solomon B, et al. Safety and efficacy of lorlatinib (PF06463922) in patients with advanced ALK+ or ROS1+ nonsmallcell lung cancer (NSCLC)［J］. J Thorac Oncol, 2017, 12(1): S383-S384. DOI: 10.1016/j.jtho.2016.11.433.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[4]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[5]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[6]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[7]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[8]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[9]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[10]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[11]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[12]	胡婷婷, 王越华. 电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[13]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[14]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[15]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.